Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium–Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease-Reference-Cited by-同舟云学术

Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium–Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

Published:2021-02-01 Issue:2 Volume:23 Page:110-119
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Kobayashi Kazuo¹²,Toyoda Masao³,Hatori Nobuo¹,Saito Nobumichi³,Kanaoka Tomohiko²,Sakai Hiroyuki¹,Furuki Takayuki¹,Umezono Tomoya¹,Ito Shun¹,Suzuki Daisuke¹,Takeda Hiroshi¹,Minagawa Fuyuki¹,Degawa Hisakazu¹,Yamamoto Hareaki¹,Machimura Hideo¹,Chin Keiichi¹,Hishiki Toshimasa¹,Takihata Masahiro¹,Aoyama Kouta¹,Umezawa Shinichi¹,Minamisawa Kohsuke¹,Aoyama Togo¹,Hamada Yoshiro¹,Suzuki Yoshiro¹,Hayashi Masahiro¹,Hatori Yutaka¹,Sato Kazuyoshi¹,Miyakawa Masaaki¹,Tamura Kouichi²,Kanamori Akira¹

Affiliation:

1. Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

2. Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

3. Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/dia.2020.0165

Reference22 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

3. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

4. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

5. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease;Hypertension Research;2023-10-17

2. The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists;Cardiovascular Endocrinology & Metabolism;2023-09-28

3. Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience;Journal of Family and Community Medicine;2023

4. Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists;Scientific Reports;2022-09-27

5. Concomitant treatment with insulin and sodium–glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score‐matched analysis;Journal of Diabetes Investigation;2022-05-20